Eculizumab

Human IgG2-IgG4 kappa

Flow cytometric analysis of 1X10⁶ HepG2 cells with Eculizumab (HY-P9914, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/50 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa Isotype Control (HY-P99002, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

Immobilized Human Complement C5 Protein (Flag Tag) can bind Eculizumab. The EC₅₀ for this effect is 3.17 ng/mL.

Eculizumab purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Nov 5;10(1):362. [Abstract]

Customer Validation
Cyclic peptide Cp1, Cp3 or anti-C5 antibody (Eculizumab)-induced erythrocyte hemolysis rate quantified by hemoglobin absorbance at 540 nm, n = 3.

Eculizumab purchased from MedChemExpress. Usage Cited in: Cell. 2025 May 29;188(11):3013-3029.e19. [Abstract]

Customer Validation
The quantification of free Hb from human RBCs as indicated in vitro (n = 4). The results showed that the administration of Eculizumab (50 mg/mL; 30 min) significantly hampered the release of free Hb induced by activated complement compared with that of controls.

Eculizumab purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Dec 8;15(1):43346. [Abstract]

Customer Validation
LDH assay results with cell lysis normalized to lysis buffer-treated cells and additional AC/IC-only background absorbance subtraction. Effects of Eculizumab on U-87MG-AQP4-ECFP cells after complement and E5415A treatment. Cells were treated with active or heat-inactivated human complement (AC/IC) in combination with E5415A (10 µg/mL). In addition to E5415A + AC, complement inhibitors against C5 (Eculizumab, 30 µg/mL) were added to the complement 15 min before the application on cells.

Eculizumab purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Dec 8;15(1):43346. [Abstract]

Customer Validation
qPCR results of genes differently expressed in U-87MG-AQP4-ECFP cells after complement and E5415A treatment. Log2-fold changes of E5415A + AC/IC with or without Eculizumab (30 µg/mL; 15 min)-treated cells were compared to untreated controls. GAPDH served as a housekeeping gene, and all ΔCt values of all genes were calculated before the normalization to untreated cells.

Eculizumab purchased from MedChemExpress. Usage Cited in: Blood Vessel Thromb Hemost. 2025 Dec 22.

Customer Validation
Effect of complement inhibition and FcγRII blockade on patient serum-induced platelet aggregation in HIMEA. Platelet aggregation induced by patients’ serum obtained during active disease (T2_Pre) in the presence of (UFH, 100 IU/mL) was reduced by treatment with the anti-C5 antibody Eculizumab (0.35 mg/mL; 20 min), the C3 inhibitor compstatin (0.12 and 0.18 mg/mL), or the FcγRII-blocking antibody IV.3 (35 μg/mL). Results are expressed as the percentage of residual platelet reactivity relative to aggregation observed with UFH 100 IU/mL alone.